Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial.

Fred Saad Egils Vjaters Neal D Shore David Olmos Nianzeng Xing Andrea Juliana Pereira de Santana Gomes Augusto César de Andrade Mota Pamela SalmanMindaugas JievaltasAlbertas UlysMaris JakubovskisEvgeny KopyltsovWeiqing HanLiina NevalaitaIsabella TestaMarie-Aude Le BerreIris KussKunhi Parambath Haresh

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)

These results confirm the efficacy and tolerability of darolutamide plus ADT in patients with mHSPC, demonstrating clinically and statistically significant improvement in rPFS and a favorable safety profile consistent with prior phase 3 darolutamide trials.

Keyphrases

phase iii
open label
prostate cancer
placebo controlled
double blind
clinical trial
phase ii
radical prostatectomy
study protocol
randomized controlled trial
cell therapy